FAP-CAR-△TGFβRII

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameFAP-CAR-△TGFβRII
Drug Alias NameFAP-CAR-△TGFβRII
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Macrophages therapy > Chimeric antigen receptor Macrophages therapy > in vivo CAR-Macrophages therapyCell and gene therapy > Cell therapy > In vivo cell therapy > in vivo CAR-Macrophages therapy
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesZhejiang UniversityCellOrigin Technology (Hangzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang University
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A